Natural Alternatives sales rallies 23% as factory overheads drag net income

Natural Alternatives International (NASDAQ:NAII) reported a double-digit increase in third-quarter revenues, but persistent manufacturing underutilization and overhead costs kept the nutritional supplement manufacturer in the red.

The Carlsbad, California-based company generated net sales of $35.5 million for the third quarter of fiscal 2026 ended March 31, 2026, marking a 23% increase compared to the $28.8 million recorded in the prior-year period.

Despite the top-line recovery, Natural Alternatives posted a net loss of $4.3 million, or $0.72 per diluted share, for the quarter.

For the first nine months of fiscal 2026, cumulative net sales rose to $108 million.

However, the nine-month net loss deepened to $7.2 million, driven by operational headwinds at the company's production facilities.

The quarterly revenue improvement was fueled primarily by an uptick in the company's private-label contract manufacturing segment, as order volumes from major customer accounts began to normalize.

Conversely, year-to-date revenue from its proprietary CarnoSyn® beta-alanine ingredient business experienced a decline, facing lower global demand volumes.

Management attributed the ongoing operating losses to elevated fixed costs and factory underutilization, particularly within its expanded domestic manufacturing infrastructure.

Because of these structural pressures, the company stated it expects to record a full-year net loss for fiscal 2026.

To stabilize its financial position, Natural Alternatives secured new debt financing to enhance its capital structure.

The company finalized an $11 million term loan and a $20 million asset-based revolving credit facility with Legacy Corporate Lending.

Management indicated that the new credit lines are designed to improve short-term liquidity, reduce compliance constraints, and provide working capital flexibility as the firm works to realign production capacity with demand.